Merck Canada appoints David D. Jones as new President and Managing Director
by CM Staff
Jones is succeeding Marwan A. Akar.
David D. Jones (CNW Group/Merck Canada Inc.)
KIRKLAND — Merck Canada appoints David D. Jones as president and Managing Director, effective September 1, 2024. Jones is succeeding Marwan A. Akar, who has held the position since June 2021.
Before his appointment at Merck Canada, Jones was VP and executive officer of primary care, specialty medicines, vaccines and rare disease for MSD Japan.
Jones holds an M.B.A. from the Robert H. Smith School of Business at the University of Maryland and a Bachelor of Science from the University of Maryland Baltimore County (UMBC). He is a graduate of the Merck/Harvard Business School Enterprise Leadership Program, the Executive Leadership Council’s Strengthening the Pipeline program, and the McKinsey Black Executive Leadership Program, and was named to the Philadelphia Business Journal’s 40 Under 40 Leaders in 2019.
Akar has been appointed to a position within Merck’s global organization. During his time in Canada, Akar led the Canadian organization through post-COVID recovery.
